Thrive II Preview

The Compound Psilocybin in Magic Mushroom Found Safe for Consumption in Largest Ever Controlled Study

Posted by on December 22, 2019 in Sci-Tech, Science with 0 Comments

By Andy Gregory | Independent

The largest controlled study of psilocybin – the psychoactive ingredient in magic mushrooms – has found the compound safe for human consumption, bringing researchers one step closer to developing a psilocybin-based treatment for depression.

Volunteers who received doses of the psychedelic compound experienced no serious adverse effects in phase one clinical trials at Kings College London (KCL).

Psilocybin has been tipped as a potentially groundbreaking treatment for mental health disorders that could replace antidepressants, with some research suggesting it could also aid those dealing with addiction.

“The results of the study are clinically reassuring and support further development of psilocybin as a treatment for patients with mental health problems that haven’t improved with conventional therapy, such as treatment-resistant depression,” said KCL’s Dr. James Rucker, the study’s lead investigator.

Most of the minor adverse events recorded were of the expected psychedelic nature, researchers found, with changes to sensory perception and mood, but no negative effects on cognitive and emotional functioning.

The phase one trials – which sought to test the compound’s safety, not its therapeutic value – compared the effects of varying doses of the psilocybin-based drug COMP360 and placebos in 89 healthy volunteers.

There were 25 dosing sessions in total. In each session, six participants would receive either 10mg or 25mg doses or a placebo during a one-on-one session with a therapist lasting roughly six hours, with a follow-up period of 12 weeks.​

Research by the company behind the trial, Compass Pathways, into using psilocybin as a treatment for depression has been fast-tracked in the US, receiving special “breakthrough therapy” status from the Food and Drug Administration.

It is currently running phase two studies across Europe and North America involving 216 patients who suffer from depression that hasn’t responded to treatment.

“This study is part of our overall clinical development program in treatment-resistant depression,” Compass Pathways’ co-founder Dr. Ekaterina Malievskaia said.


Tags: , , , , , ,


If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on YouTube

New Title

NOTE: Email is optional. Do NOT enter it if you do NOT want it displayed.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

FAIR USE NOTICE. Many of the articles on this site contain copyrighted material whose use has not been specifically authorized by the copyright owner. We are making this material available in an effort to advance the understanding of environmental issues, human rights, economic and political democracy, and issues of social justice. We believe this constitutes a 'fair use' of the copyrighted material as provided for in Section 107 of the US Copyright Law which contains a list of the various purposes for which the reproduction of a particular work may be considered fair, such as criticism, comment, news reporting, teaching, scholarship, and research. If you wish to use such copyrighted material for purposes of your own that go beyond 'fair use' must obtain permission from the copyright owner. And, if you are a copyright owner who wishes to have your content removed, let us know via the "Contact Us" link at the top of the site, and we will promptly remove it.

The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Conscious Life News assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms.

Paid advertising on Conscious Life News may not represent the views and opinions of this website and its contributors. No endorsement of products and services advertised is either expressed or implied.
Send this to a friend